ID HeLa-APL AC CVCL_9493 SY HeLa-R DR Wikidata; Q54882709 RX PubMed=15365569; RX PubMed=17338558; CC Population: African American. CC Selected for resistance to: ChEBI; CHEBI_90205; Plitidepsin (Dehydrodidemnin B; Aplidin). CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18). CC Omics: Proteomics; 2DE-MS. CC Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002. DI NCIt; C27677; Human papillomavirus-related endocervical adenocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_0030 ! HeLa SX Female AG 30Y6M CA Cancer cell line DT Created: 06-06-12; Last updated: 10-04-25; Version: 18 // RX PubMed=15365569; DOI=10.1038/sj.bjc.6602166; PMCID=PMC2409906; RA Losada A., Lopez-Oliva J.M., Sanchez-Puelles J.M., RA Garcia-Fernandez L.F.; RT "Establishment and characterisation of a human carcinoma cell line RT with acquired resistance to aplidin."; RL Br. J. Cancer 91:1405-1413(2004). // RX PubMed=17338558; DOI=10.1021/pr060430+; RA Gonzalez-Santiago L., Alfonso P., Suarez Y., Nunez A., RA Garcia-Fernandez L.F., Alvarez E., Munoz A., Casal J.I.; RT "Proteomic analysis of the resistance to aplidin in human cancer RT cells."; RL J. Proteome Res. 6:1286-1294(2007). //